The Food and Drug Administration upgraded the designation of Pfizer Inc.'s (NYSE: PFE) McPherson facility as Voluntary Action Indicated which clears a path for the marketing approval of Achaogen Inc.'s (Nasdaq: AKAO) plazomiein. Shares of Pfizer dropped $1.22 to close at $37.80 while Achaogen stock gained $1.11 to close at $12.17.
Achaogen's path to approval cleared
January 30, 2018 at 16:36 PM EST
